PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
37.66
+0.01 (+0.03%)
At close: 4:02PM EDT

37.66 0.00 (0.00%)
After hours: 4:23PM EDT

Stock chart is not supported by your current browser
Previous Close37.65
Open37.59
Bid37.60 x 45100
Ask37.73 x 2900
Day's Range37.48 - 37.73
52 Week Range32.32 - 39.43
Volume19,709,297
Avg. Volume20,408,223
Market Cap220.295B
Beta0.92
PE Ratio (TTM)10.46
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.66%)
Ex-Dividend Date2018-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board
    Yahoo Finance Video5 hours ago

    Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board

    Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!

  • MarketWatch1 hour ago

    Pfizer, Eli Lilly non-opioid pain drug nears finish line

    A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.

  • TheStreet.com2 hours ago

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • Novartis hints at 2018 outlook hike despite drug price freeze
    Reuters4 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • The Wall Street Journal6 hours ago

    [$$] Novartis Won't Raise U.S. Drug Prices This Year

    Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.

  • Reuters8 hours ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.

  • Reuters8 hours ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.

  • Benzinga8 hours ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...

  • Reuters10 hours ago

    Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

    London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.

  • Reuters10 hours ago

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
    Bloomberg14 hours ago

    Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.

    Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.

  • Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
    Bloomberg14 hours ago

    Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year

    Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.

  • Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
    Zacksyesterday

    Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

    Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

  • Investopediayesterday

    TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise

    Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.